$20.38 Million in Sales Expected for The Medicines Company (MDCO) This Quarter
Wall Street analysts predict that The Medicines Company (NASDAQ:MDCO) will announce $20.38 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for The Medicines’ earnings. The highest sales estimate is $26.80 million and the lowest is $16.52 million. The Medicines reported sales of $25.20 million in the same quarter last year, which indicates a negative year over year growth rate of 19.1%. The business is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that The Medicines will report full year sales of $20.38 million for the current financial year, with estimates ranging from $76.35 million to $86.70 million. For the next year, analysts expect that the business will report sales of $63.70 million per share, with estimates ranging from $23.96 million to $124.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover The Medicines.
The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The firm had revenue of $16.87 million during the quarter, compared to analyst estimates of $26.06 million. During the same quarter in the prior year, the business posted ($0.64) earnings per share. The company’s quarterly revenue was down 55.1% compared to the same quarter last year.
Shares of The Medicines (NASDAQ:MDCO) opened at $28.34 on Tuesday. The company has a debt-to-equity ratio of 3.42, a quick ratio of 1.79 and a current ratio of 2.31. The Medicines has a fifty-two week low of $27.77 and a fifty-two week high of $55.95.
In related news, Director Alexander J. Denner purchased 170,000 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The shares were acquired at an average cost of $30.03 per share, with a total value of $5,105,100.00. Following the completion of the purchase, the director now directly owns 6,663 shares of the company’s stock, valued at $200,089.89. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.22% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in MDCO. FMR LLC boosted its position in shares of The Medicines by 1.1% during the second quarter. FMR LLC now owns 10,825,038 shares of the company’s stock worth $411,460,000 after purchasing an additional 117,982 shares in the last quarter. Iridian Asset Management LLC CT boosted its position in shares of The Medicines by 21.7% during the second quarter. Iridian Asset Management LLC CT now owns 3,677,746 shares of the company’s stock worth $139,791,000 after purchasing an additional 655,065 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in shares of The Medicines by 21.9% during the third quarter. Westfield Capital Management Co. LP now owns 2,476,778 shares of the company’s stock worth $91,740,000 after purchasing an additional 445,419 shares in the last quarter. State Street Corp boosted its position in shares of The Medicines by 9.0% during the second quarter. State Street Corp now owns 2,220,199 shares of the company’s stock worth $84,391,000 after purchasing an additional 183,086 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of The Medicines by 24.1% during the second quarter. Franklin Resources Inc. now owns 1,765,169 shares of the company’s stock worth $67,093,000 after purchasing an additional 343,160 shares in the last quarter.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.